What long‑acting oral muscle relaxant is recommended for chronic spasticity or persistent muscle spasm?

Long-Acting Oral Muscle Relaxants for Chronic Spasticity

For chronic spasticity or persistent muscle spasm, tizanidine and oral baclofen are the recommended long-acting oral muscle relaxants, with tizanidine specifically preferred for chronic stroke patients due to superior evidence for maintaining motor strength while reducing spasticity and pain. 1

Primary Recommendations by Clinical Context

For Chronic Stroke-Related Spasticity

• Tizanidine is the first-line choice for chronic stroke patients, demonstrating efficacy in reducing spasticity and pain without loss of motor strength 1
• Oral baclofen is an alternative but may cause more sedation and has less impact on spasticity in stroke compared to other conditions 1
• Dantrolene is a third option with the benefit of no cognitive side effects, though evidence is more limited 1

For Spasticity from CNS Injury or Demyelinating Disease

• Baclofen is the established choice for severe spasticity from central nervous system injury, demyelinating conditions, and other neuromuscular disorders 2
• Start with low doses and titrate gradually to minimize dizziness, somnolence, and gastrointestinal symptoms 2
• Critical warning: Discontinuation after prolonged use requires slow tapering to avoid withdrawal toxicity including delirium and seizures 2

Comparative Evidence: Tizanidine vs. Baclofen

A head-to-head trial in multiple sclerosis patients found 3:

• Both medications similarly improved overall spastic state, spasms, and clonus
• Tizanidine showed superior improvement in muscle strength, bladder function, and activities of daily living
• Optimal tizanidine dosing: 8-36 mg daily
• Optimal baclofen dosing: 10-80 mg daily
• Side effect profiles differ: tiredness with tizanidine vs. muscle weakness with baclofen

Drugs to Avoid

Contraindicated or Not Recommended

• Diazepam and benzodiazepines: Contraindicated during stroke recovery due to deleterious effects on neurological recovery, plus sedation and fall risk 1, 2
• "Muscle relaxants" (cyclobenzaprine, carisoprodol, methocarbamol, chlorzoxazone, metaxalone): Not recommended for chronic pain or spasticity 4, 2
  • These drugs do not directly relax skeletal muscle
  • Effects are nonspecific and unrelated to actual muscle relaxation
  • High risk for falls in older adults
  • Cyclobenzaprine is essentially identical to amitriptyline with similar adverse effects
  • Carisoprodol has abuse potential and was removed from European markets

Dosing Considerations

Baclofen

• Standard dosing typically does not exceed 80 mg daily per conventional guidelines
• However, some patients require high-dose baclofen (significantly exceeding 80 mg/day) for adequate relief 5
• High-dose baclofen shows longer time-to-peak plasma levels and half-lives than previously reported
• Blood levels may rise gradually over time on stable dosing, particularly with impaired renal clearance
• Monitor renal function closely, especially in patients with neurogenic bladder

Tizanidine

• Effective dose range: 8-36 mg daily 3
• Titrate gradually to minimize adverse effects
• Primary side effect: tiredness

Clinical Pitfalls to Avoid

1. Do not prescribe traditional "muscle relaxants" believing they relieve muscle spasm - they don't work through muscle relaxation mechanisms 2

2. Never abruptly discontinue baclofen after prolonged use - requires slow taper to prevent withdrawal seizures and delirium 2

3. Avoid benzodiazepines for chronic spasticity despite their GABA-A agonist properties - the risk-benefit ratio is unfavorable, particularly fall risk and cognitive effects 4, 1, 2

4. Don't use these medications in isolation - combine with positioning, range of motion exercises, stretching, and splinting for optimal outcomes 1

5. Perioperatively, hold all muscle relaxants on day of surgery to avoid interactions with anesthetic agents 6

When Oral Therapy Fails

For refractory chronic spasticity despite oral medications 1:

• Intrathecal baclofen via implanted pump for chronic stroke patients (>6 months post-stroke)
• Botulinum toxin or phenol/alcohol injections for focal disabling spasticity
• Neurosurgical procedures (selective dorsal rhizotomy, dorsal root entry zone lesions) as last resort

Treatment Goals

Initiate pharmacotherapy when spasticity results in 1:

• Pain
• Poor skin hygiene
• Decreased function
• Risk of contracture development

The goal is symptomatic relief to increase functional capacity, not complete elimination of tone (which may be beneficial for ambulation in some patients).